The impact of HIV drug resistance testing on changes to treatment-Reference-Cited by-同舟云学术

The impact of HIV drug resistance testing on changes to treatment

Published:2011-03-13 Issue:5 Volume:25 Page:603-610
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Bansi Loveleen,Smith Colette,Phillips Andrew,Kirk Stuart,Geretti Anna-Maria,Johnson Margaret,Mackie Nicola,Post Frank,Gazzard Brian,Dunn David,Sabin Caroline

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference9 articles.

1. BHIVA guidelines 2008.;Gazzard;HIV Med,2008

2. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.;Hirsch;Clin Infect Dis,2008

3. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study.;HIV Med,2004

4. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA);Cingolani;AIDS,2002

5. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response;Nieuwkerk;Antivir Ther,2001

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic accuracy of AS-OCT vs gonioscopy for detecting angle closure: a systematic review and meta-analysis;Graefe's Archive for Clinical and Experimental Ophthalmology;2021-07-05

2. A cell-free enzymatic activity assay for the evaluation of HIV-1 drug resistance to protease inhibitors;Frontiers in Microbiology;2015-10-31

3. Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003–2012 decade in Italy;BMC Infectious Diseases;2014-07-18

4. The cost of antiretroviral drug resistance in HIV-positive patients;Antiviral Therapy;2013

5. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors;International Journal of STD & AIDS;2012-07